Key Highlights
● Skye Bioscience discontinued its Phase 2a CBeyond trial of nimacimab in obesity on August 14, 2026.
● The company is merging into fibrosis-focused Fibrx, a complete strategic pivot away from its former obesity focus.
● Nimacimab is a peripherally restricted CB1 receptor antibody that was previously being developed as an obesity treatment.
● Skye Bioscience, based in San Diego, is no longer an obesity pure-play following the trial discontinuation and Merger announcement.
Skye Bioscience, the San Diego-based clinical-stage biotech that had been developing nimacimab, a peripherally restricted CB1 receptor antibody for obesity, is no longer an obesity pure-play. On August 14, 2026, the company disclosed it discontinued its Phase 2a CBeyond trial of nimacimab during the second quarter and simultaneously announced a transaction to combine with U.K. fibrosis specialist Redx Pharma, forming a new entity called Fibrx Therapeutics backed by roughly $125 million in fresh financing. Shares, which traded as high as $4.99 over the past year, closed near $0.50 on August 14, down about 7.3% that day and more than 82% over 12 months, after having already touched a 52-week low of $0.276 on August 6. Legacy Skye shareholders will retain only contingent rights to any future value from nimacimab.
Latest Development
The headline event is a corporate pivot, not a clinical readout. Per Skye's press release and related SEC filing, Skye will acquire Redx Pharma via a U.K. scheme of arrangement, with the combined company renamed Fibrx Therapeutics and expected to keep trading on Nasdaq. The transaction is paired with roughly $125 million in committed financing: a $67.9 million private placement, a $36 million Redx Series A round led by Abingworth, and up to $22 million from an Equity line Facility tied to Redmile. Management said the proceeds are intended to fund operations into 2029. The deal is expected to close in the fourth quarter of 2026, subject to Shareholder votes, regulatory clearances, Nasdaq approval and U.K. High Court sanction.
Under the terms disclosed, pre-transaction Redx holders would own approximately 46.2% of the combined company, incoming financing investors approximately 48.5%, and existing Skye shareholders just roughly 5.4%, reflecting how dilutive the Recapitalization is to current SKYE holders. In place of continued equity upside from nimacimab, Skye shareholders are set to receive one contingent value right (CVR) per share entitling them to 90% of any net proceeds from a future sale or licensing of nimacimab and related intellectual property, capped at a 12-month realization window post-closing. Redx's lead program, RXC008, described as a gut-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease that holds FDA Fast Track Designation granted in January 2026, becomes the combined company's flagship asset, with Phase 2 data not expected until the second half of 2028. The companies also reported combined Q2 2026 results the same day: Skye's standalone R&D spend fell sharply to $3.9 million from $14.3 million a year earlier, reflecting the CBeyond trial's termination, while cash and short-term investments stood at just $10.1 million as of June 30, 2026, down from $25.7 million at the end of 2025.
What the Numbers Show
Skye's market capitalization has collapsed to roughly $17–19 million, a fraction of where it traded even a few months ago. The company burned through $15.7 million in operating cash in the first half of 2026 alone, and by the June 30 balance-sheet date held only $10.1 million in cash and short-term investments, a level that, absent the Redx transaction and its associated financing, would have left Skye with a thin runway. As recently as its Q1 2026 update (reported in May), management said existing capital was expected to fund operations only "through the fourth quarter of 2026," and that guidance explicitly excluded costs for an anticipated Phase 2b study, underscoring how capital-constrained the standalone obesity program had become before it was shelved. Analyst coverage has been in flux: Craig-Hallum downgraded the stock from Buy to Hold in October 2025 with a $2.00 target, while other firms had maintained more bullish targets earlier in the CBeyond data cycle; those targets predate the trial's discontinuation and the announced share-count dilution and should be read with that context in mind.
Why Investors Are Paying Attention
Nimacimab had drawn interest as a differentiated, non-GLP-1 mechanism in obesity, a peripherally restricted CB1 inhibitor designed to avoid the central-nervous-system side effects that doomed earlier CB1 drugs like rimonabant. Topline Phase 2a data reported in October 2025 showed nimacimab monotherapy missed its primary endpoint (placebo-adjusted weight loss of roughly 1.3%, not statistically significant), but the combination arm with semaglutide showed an added roughly 3-percentage-point weight-loss benefit over semaglutide alone, without an apparent added GI tolerability burden, the kind of "combo enhancer" data that some investors hoped could carve out a niche alongside dominant GLP-1s from Novo Nordisk and Eli Lilly. That promise is now effectively shelved: the trial was discontinued in Q2 2026, and Skye's own disclosures cite "the evolving landscape for anti-obesity medicines and the commercial opportunity" as the reason. Investors are now grappling with a wholesale re-rating, from an obesity binary-catalyst story to a reverse-merger-into-fibrosis story with an uncertain payoff via CVRs.
Bull Case
Proponents could argue the Redx combination solves Skye's most pressing problem, capital, by bringing roughly $125 million and a runway into 2029, while giving shareholders CVR-based optionality on nimacimab if a partner emerges to fund further development, without Skye bearing that cost itself. RXC008's Fast Track designation and its differentiated gut-restricted ROCK-inhibitor mechanism give the combined company a clinical asset advancing toward Phase 2 data, potentially offering fresh catalysts under new leadership.
Bear Case
Existing SKYE shareholders face severe dilution, ending up with roughly 5% of the combined entity while losing direct exposure to nimacimab beyond a time-limited CVR that may pay nothing if no buyer emerges within 12 months. The deal must clear shareholder votes, Nasdaq relisting requirements, and U.K. court sanction before an expected Q4 2026 close, leaving execution risk. Cash was already thin ($10.1 million) heading into the announcement, and Redx's own pipeline catalyst (RXC008 Phase 2 data) is not expected until H2 2028, a long wait with no near-term readout to support the stock.
What Could Move the Stock Next?
Near-term catalysts include the Fibrx shareholder votes and regulatory/Nasdaq approvals needed to close the transaction, any news on a nimacimab licensing partner that would activate CVR value, further financing or dilution disclosures, and Redx-related pipeline updates as the combined company defines its go-forward strategy ahead of the targeted Q4 2026 close.
A Full Pivot Away From Obesity
Skye Bioscience has effectively exited the obesity race it entered with nimacimab, discontinuing its CBeyond Phase 2a trial and agreeing to merge into a new, fibrosis-focused entity, Fibrx Therapeutics, backed by roughly $125 million in financing but heavily diluting existing shareholders in the process. The stock's collapse to roughly $0.50, from a 52-week high near $5, reflects both the shelved obesity program and the market's repricing of a company now defined by a pending Reverse merger rather than a clinical asset investors originally bought into. What happens next hinges on deal execution, Nasdaq and shareholder approvals, and whether the CVR attached to nimacimab ultimately delivers any value.






Please wait processing your request...